Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial
NCT ID: NCT05146635
Last Updated: 2022-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
110 participants
INTERVENTIONAL
2021-12-01
2023-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer
NCT02214602
Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.
NCT02438865
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
NCT05626101
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
NCT05084586
Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer
NCT04319263
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Both the natural history of non-muscle-invasive bladder cancer (NMIBC) and its treatment strategies are highly variable. Although some patients never experience disease recurrence, others experience disease progression and eventually die of their disease .
In the absence of intravesical treatment, a patient with non-muscle-invasive BC has a 47% probability of disease recurrence within 5 years of diagnosis and a 9% probability of progression to muscle-invasive disease .
Low-, intermediate- and high-risk categories have been defined to help guide the treatment of patients with NMIBC (Ta, T1, and CIS). Treatment of NMIBC is now relatively well-defined for high-risk and low-risk disease presentation, and awaits further refinement through improvements in therapeutic options .
Solitary low-grade tumors, especially smaller lesions (3 cm or less), respond best to resection and immediate instillation of intravesical agents, whereas higher risk lesions, such as carcinoma in situ and high-grade T1 stage disease, have demonstrated good response to BCG when given on a schedule of induction (an initial 6-week course) and maintenance (3-weekly courses every 6 months for 3 years) .
However, while low- and high-risk diseases have been well-classified, the intermediate-risk (IR) category has traditionally comprised a heterogeneous group of patients that do not fit into either of these categories . As a result, many urologists remain uncertain about the categorization of patients as 'intermediate-risk' as well as the selection of the most appropriate therapeutic option for this patient population .
The pathology of IR NMIBC has been defined by different organizations (American Urological Association, European Association of Urology, National Comprehensive Cancer Network, and International Consultation on Urological Diseases) as those patients with recurrent (\<1 year) low-grade Ta disease, solitary low-grade Ta \>3cm, multifocal low-grade Ta disease or high-grade Ta disease \<3 cm .
Current recommendations for therapy from the aforementioned organizations suggest a basic role for induction and maintenance therapy with either immunotherapy or chemotherapy. Data from a number of recent trials suggest that BCG with maintenance is superior to maintenance chemotherapy in this population as regard to recurrence free survival. On the other hand, no significant benefit of BCG compared with chemotherapy for tumor progression was identified.
Most of these studies were limited by its heterogeneity of patients (non-standardized definition of IR) and non-unified regimen of intravesical treatment (course or utilized chemotherapeutic agent). A well-designed randomized controlled trial with a rigorous methodology is warranted to provide a solid evidence for best practice in this special group of patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intravesical immunotherapy (BCG) group
Intravesical Bcg
Patients will receive induction and maintenance BCG after complete TURBT.
Intravesical chemotherapy (Epirubicin) group
Intravesical chemotherapy (epirubicin)
Patients will receive induction and maintenance epirubicin after complete TURBT.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravesical Bcg
Patients will receive induction and maintenance BCG after complete TURBT.
Intravesical chemotherapy (epirubicin)
Patients will receive induction and maintenance epirubicin after complete TURBT.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with primary or recurrent papillary NMIBC.
* Complete TURBT.
* Patients with IR NMIBC confirmed by histopathology.
Exclusion Criteria
* Patients with history of previous radiotherapy or systemic chemotherapy.
* Patients suffering from immuno-deficiency or other malignancies.
* Patients with history of hypersensitivity reaction to BCG or epirubicin.
* Examination under anesthesia (EUA) reveals palpable bladder mass.
* Patients with low or high risk NMIBC by histopathology
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr Abdel-Lateif El-Sawy
Lecturer of Urology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amr A Elsawy
Role: PRINCIPAL_INVESTIGATOR
Mansoura University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mansoura Urology and Nephrology Center
Al Mansurah, DK, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AE-12-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.